Skip to content

Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients

Efficacy and Safety of Benjakul Extract Capsules and Loratadine for Treatment Allergic Rhinitis Patients (Clinical Trial Phase II)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03376594
Enrollment
60
Registered
2017-12-18
Start date
2017-07-30
Completion date
2018-03-31
Last updated
2018-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

Benjakul Extract, Allergic Rhinitis, Herbal Medicine

Brief summary

1. To compare the effectiveness of Benjakul extract capsules at 300 mg per day with Loratadine drug in the treatment of allergic rhinitis patients in small group (Clinical Trial Phase II). 2. To study the safety and side effects of Benjakul extract capsules 300 mg per day and Loratadine drug for allergic rhinitis patients.

Detailed description

1. Group 1consists of 30 patients, taking Benjakul dosage 100 mg or 1 capsule 3 times daily. beforeBreakfast, lunch and dinner. 2. Group 2 consists of 30 patients, taking Loratadine dosage 100 mg 1time daily.Taking drug is as follows Volunteers will be treated by drugs continuously for a period of six weeks. Taking three times a day 1 tablet before meals (breakfast, lunch, dinner), giving drug based on random. Volunteers groups receiving Benjakul take 1capsule 3 times daily. Volunteer groups receiving Loratadine take loratadine tablet first 1capsule 1 time daily and then taking placebo once 1 capsule during the day and 1 capsule in the evening. Patients have to report all the 42 days (6 weeks). The blood and urine samples will be collected and evaluated before the treatment and later following symptoms after 21 and 42 days (3 weeks and 6). Assessment methods to measure the nasal, other of nasal symptoms, assessment of quality of life and overall treatment (Global assessment),Acoustic Rhinometry and tools which are used to evaluate nasal congestion. measuring the narrowest cross-sectional area of the nasal cavity, this tool takes a short time to evaluate and can determine volume of nasal cavity by calculating of the CSA in the nasal cavity. In addition, the researchers areable to check the safety of using medications by taking blood and urine samples to check Hematology CBC, Lipid profile, FBS monitoring of renal function (Renal function test) and liver function tests (Liver Function Tests: LFTs). So, the volunteers must NPO before every blood drawing.

Interventions

DRUGBenjakul Extract

30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.

DRUGLoratadine

30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.

Sponsors

Thammasat University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Grouping uses Randomize controlled trial (RCT) and groups by using Random allocation by means of Simple Randomization as well as using the code with BJK followed by 3 digits (BJK001, BJK002, ...) and treating in double blinding form.

Intervention model description

RCT

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female patients aged between 20-70 years * Patients have history of allergic rhinitis on the basis of Allergic Rhinitis and its Impact on Asthma : ARIA (itching and nasal obstruction, watery nasal discharge, sneezing ,congestion) * Patients have moderate allergic rhinitis diagnosed by doctor with a minimum TNSS score of 5 points * No history of disease : heart disease, kidney disease, liver disease, epilepsy,high blood pressure and severe asthma. * Normal results in blood test, liver and kidney. * Not pregnant or breastfeeding. * Body Mass Index (BMI) 18-35 kg / m2 and normal vital signs. * Volunteers are willing participants.

Exclusion criteria

* Volunteers who have taken anti-coagulant and anti-platelet aggregation drugs. * Patients receiving Intranasal steroids. * Volunteers who get serious side effect from loratadine : fatigue, headache, dry mouth, drowsiness, nausea, stomach ulcers, rash. * Volunteers who have side effects from Benjakul drug. * Volunteers who have a temperature. * Volunteers participating in other research. * Volunteers who have severe urticaria and anaphalaxis. * Volunteers who are immunocompromised or have with severe chronic diseases, such as AIDS. * Volunteers who have taken Macrolides : erythromycin, clarithromycin, Imidazole (ketoconazole, itraconazole, fluconazole) HIV protease Inhibitors, Other drugs that inhibit the enzyme CYP450: cimetidine,metronidazole,zafirlukast, SSRIS * Volunteers are using drug which extract QT interval, such as Calcium Channel Blockers (eg bepridil, verapamil), Tricyclic Antidepressant, Cisapride, Quinidine and so on. * Volunteers have nasal septum perforation or have had sinus surgery

Design outcomes

Primary

MeasureTime frameDescription
Nasal clavity42 daysefficacy of the treatments on nasal symptoms and clavity by acoustic rhinometry

Secondary

MeasureTime frameDescription
Adverse event42 daysClinical symptoms, Laboratory blood and urine test
Quality of life42 daysquality of life of the patientts by Rhinoconjunctivitis quality of life Questionare (Rcq36)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026